Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells

Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome. However, how DNA mutation occurs, particularly the T315I mutation, remains unclear. In the current study, the mutagenesis of BCR-A...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Med Rep
Egile Nagusiak: Dong, Yan, Gao, Xiaotong, Zhao, Yingxin, Wei, Mengying, Xu, Lingmin, Yang, Guodong, Liu, Li
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2017
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5779997/
https://ncbi.nlm.nih.gov/pubmed/29152650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mmr.2017.7835
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak